Columbus Venture Partners has acquired Sermes CRO for an undisclosed amount, marking a significant expansion in the clinical research sector. Sermes CRO, a full Contract Research Organization with 27 years of experience, provides comprehensive clinical research services throughout the entire drug development cycle, from early phases to post-marketing studies. The acquisition integrates Sermes CRO's established expertise and operational capabilities.
Sermes CRO offers a wide range of services crucial for global clinical trials, including clinical operations, study start-up, pharmacovigilance, legal representation, regulatory advice, data management, and qualified outsourced staff. The company is recognized for its strong scientific, therapeutic, and regulatory expertise, ensuring studies are delivered within time, quality, and profitability targets. Notably, Sermes CRO has been part of the EMA’s Clinical Trial Information System (CTIS) working group since 2017 and operates an Advanced Therapies Unit providing specialized counseling on regulatory requirements for complex projects.
A key strategic driver for this acquisition is Sermes CRO's innovative Artificial Intelligence and Big Data Unit, which delivers unique clinical research data, expert analysis, and business intelligence solutions. This capability, combined with its deep experience in advanced therapies, positions Sermes CRO at the forefront of evolving drug development methodologies. The integration is expected to create substantial synergies, enhancing service offerings and accelerating the development of new therapies by leveraging Sermes CRO's robust operational framework and cutting-edge technological units.
This acquisition by Columbus Venture Partners is poised to strengthen its presence in the life sciences ecosystem by incorporating a highly specialized and experienced CRO. The combined entity will offer clients a more comprehensive and technologically advanced suite of clinical research services, streamlining the drug development process and addressing the complex needs of modern therapeutic innovation. The move underscores a commitment to advancing clinical research through integrated expertise and advanced data capabilities.